ADD A CATEGORY
JAN 24, 2013 - Benzinga
A Must Read - Share
Pfizer (NYSE: PFE) announced today that a Phase 4 study assessing the efficacy and safety of Toviaz® (fesoterodine fumarate) 8 mg once daily in patients with overactive bladder (OAB) compared to Toviaz 4 mg once daily or placebo met its primary endpoint.
Editor's Picks
Show More
Show Less
Hey you have no friends!!! Get to work and start inviting friends to help build your Comunitee. Click Here to invite friends.